DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DEXCOM INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$85.98−0.06 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $33.54B
- P/E (TTM)
- 34.1
- Dividend yield
- –
DEXCOM INC revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $933.40M | $832.30M | $891.50M | $851.90M | $841.00M | $750.50M | $802.80M | $701.90M | $731.90M | $653.20M | $769.10M | $713.60M | 71.3% | +11.0% |
| International | $375.00M | $359.60M | $368.10M | $357.40M | $316.10M | $285.50M | $310.70M | $292.30M | $272.40M | $267.80M | $265.40M | $261.40M | 28.7% | +18.6% |
From the segment and revenue-disaggregation notes of Dexcom's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.